Go back to Resources

Dose-Related Safety and Immunogenicity of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults

May-06

Journal Article

Authors:

Treanor, J.J.

Schiff, G.M.

Couch, R.B.

Cate, T.R.

Brady, R.C.

Hay, C.M.

Wolff, M.C.

She, D.

Cox, M.J.C.

Secondary:
J Infec Dis

Volume:
193

Pagination:
1223-1228

URL:
http://www.ncbi.nlm.nih.gov/pubmed/16586358

Keywords:
Antibodies-Viral; Baculoviridae; Dose-Response Relationship-Immunologic; Hemagglutinin Glycoproteins- Influenza Virus; Influenza Vaccines; Maximum Tolerated Dose; trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine; Vaccines-Inactivated

Abstract:
<p>BACKGROUND: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA. CONCLUSIONS: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.</p>

Go back to Resources